百利天恒 (688506)

Sichuan Biokin Pharmaceutical Co., Ltd.

KSH

Tags

300 Non-Cyclical IndexMSCI Component StocksSSE 180 IndexSSE Mid Cap IndexCSI 200 IndexInnovative DrugsChemical PharmaceuticalsPharmaceutical ManufacturingPharmaceuticals and HealthcareSTAR and ChiNext 50 IndexGuozheng Growth IndexFund Heavy PositionsLarge Cap GrowthLarge Cap StocksPrivate Placement StocksIntensive Research CoverageCSI 300 IndexOverseas BusinessHundred-Yuan StocksSTAR Market 50 IndexSTAR Market Biotechnology IndexConcentrated ShareholdingMargin Trading and Securities LendingNon-Cyclical StocksHigh Price-to-Book Ratio

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 41287.38
  • Circulating A-Shares(W): 10289.11
  • Earnings Per Share(RMB): -1.2300
  • Net Assets Per Share(RMB): 17.3682
  • Operating Revenue(W RMB): 206589.53
  • Total Profit(W RMB): -18559.17
  • **Net Profit Attributable to Parent(W RMB) **: -49451.59
  • Net Profit Growth Rate(%): -112.16
  • Weighted Return on Equity(%): -13.5900
  • Operating Cash Flow Per Share(RMB): -4.5840
  • Undistributed Profit Per Share(RMB): 5.0633
  • Capital Reserve Per Share(RMB): 11.2602

2. Main Business

The main business covers:

  • Pharmaceutical R&D
  • Production and marketing
  • Innovative biological drug business segment and chemical drug preparations, traditional Chinese medicine preparations business segments

3. Company Basic Information

  • Company Name: Sichuan Baili Tianheng Pharmaceutical Co., Ltd.
  • Listing Date: 2023-01-06
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 1, Building 1, No. 161 Baili Road, Chengdu Cross-Strait Science and Technology Industrial Park, Wenjiang District, Chengdu, Sichuan Province
  • Website: https://www.baili-pharm.com/
  • Company Profile: The company was established through the overall transformation of Tianheng Co., Ltd., founded in 2011, mainly engaged in pharmaceutical R&D, production and marketing. On October 15, 2011, Tianheng Co., Ltd. held an interim shareholders' meeting, and all shareholders unanimously agreed to jointly sponsor the establishment of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. through overall transformation, based on the audited net assets as of July 31, 2011, converting into 10,372 million shares with a par value of RMB 1 per share, and the remaining net assets were included in capital reserve.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 OAP III (HK) Limited Legal Person 2852.72 27.73
2 China Europe Healthcare Hybrid Securities Investment Fund Class A Fund 555.78 5.40
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 289.57 2.81
4 ChinaAMC SSE STAR Market 50 Constituents ETF Fund 283.37 2.75
5 E Fund SSE STAR Market 50 Constituents ETF Fund 229.92 2.23
6 China Universal Innovation Pharmaceutical Theme Hybrid Securities Investment Fund Class A Fund 170.36 1.66
7 Yongwin Pharmaceutical Innovation Smart Selection Hybrid Initiated Securities Investment Fund Class A Fund 164.98 1.60
8 CITIC Securities - Industrial Bank - CITIC Securities Baili Tianheng Employee Participation in STAR Market Strategic Placement Collective Asset Management Plan Legal Person 140.89 1.37
9 Huatai-Pinebridge CSI 300 ETF Fund 140.57 1.37
10 GF Healthcare Equity Securities Investment Fund Class A Fund 138.36 1.34

5. Concept Sectors

  • Innovative Drugs
  • Margin Trading
  • Large Cap Stocks
  • High P/B Ratio
  • Heavy Fund Holdings
  • Private Placement Stocks
  • Hundred-Yuan Stocks
  • MSCI Constituent
  • Intensive Research
  • Overseas Business
  • Concentrated Ownership
  • Non-Cyclical Stocks
  • SSE 180
  • SSE Mid Cap
  • Large Cap Growth
  • SZSE Growth
  • CSI 300
  • CSI 200
  • 300 Non-Cyclical
  • STAR Market 50
  • Innovation and Entrepreneurship 50
  • STAR Market Biotechnology

Remarks

  • Data update date: 2025-09-30
  • Data source: Public market information